ArticleJournal of immunology (Baltimore, Md. : 1950)2020
Establishment of a Pig Influenza Challenge Model for Evaluation of Monoclonal Antibody Delivery Platforms.
Article in Journal of immunology (Baltimore, Md. : 1950), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Phenotypic and functional changes to porcine monocyte-derived macrophages triggered by IL-1β and its receptor antagonist IL-1Ra.Frontiers in immunology · 2026Article
- Human and porcine IgG subclasses differentially engage porcine Fc receptors.Discovery immunology · 2026Article
- Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial.Nature medicine · 2025Article
- Aerosol and intranasal delivery of monoclonal antibodies to prevent transmission in pig influenza infection models.NPJ vaccines · 2025Article
- Real-Time Auto-Monitoring of Livestock: Quantitative Framework and Challenges.Sensors (Basel, Switzerland) · 2025Review
- Review
- Biocompatibility of Water-Dispersible Pristine Graphene and Graphene Oxide Using a Close-to-Human Animal Model: A Pilot Study on Swine.Advanced healthcare materials · 2025Article
- An effective vaccine against influenza A virus based on the matrix protein 2 (M2).Veterinary microbiology · 2024Article
- Evaluation of a novel intramuscular prime/intranasal boost vaccination strategy against influenza in the pig model.PLoS pathogens · 2024Article
- Single-cell analysis reveals lasting immunological consequences of influenza infection and respiratory immunization in the pig lung.PLoS pathogens · 2024Article
- Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases.Pharmaceutics · 2024Review
- Comparative pharmacokinetics of porcine and human anti-influenza hemagglutinin monoclonal antibodies in outbred pigs and minipigs.Frontiers in immunology · 2024Article
- Heterogeneity of Phenotypic and Functional Changes to Porcine Monocyte-Derived Macrophages Triggered by Diverse Polarizing Factors In Vitro.International journal of molecular sciences · 2023Article
- Simultaneous co-infection with swine influenza A and porcine reproductive and respiratory syndrome viruses potentiates adaptive immune responses.Frontiers in immunology · 2023Article
- Goat milk extracellular vesicles: immuno-modulation effects on porcine monocyte-derived macrophagesFrontiers in immunology · 2023Article
- A direct contact pig influenza challenge model for assessing protective efficacy of monoclonal antibodies.Frontiers in immunology · 2023Article
- Engineered DNA-encoded monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein confer single dose protection in a murine malaria challenge model.Scientific reports · 2022Article
- Spatial, temporal and molecular dynamics of swine influenza virus-specific CD8 tissue resident memory T cells.Mucosal immunology · 2022Article
- Fc-Mediated Functions of Porcine IgG Subclasses.Frontiers in immunology · 2022Article
- Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model.Frontiers in oncology · 2022Article
Corrections and comments
- Comment on
Authors and funding
26 authors.
Funding
Abstract
mAbs are a possible adjunct to vaccination and drugs in treatment of influenza virus infection. However, questions remain whether small animal models accurately predict efficacy in humans. We have established the pig, a large natural host animal for influenza, with many physiological similarities to humans, as a robust model for testing mAbs. We show that a strongly neutralizing mAb (2-12C) against the hemagglutinin head administered prophylactically at 15 mg/kg reduced viral load and lung pathology after pandemic H1N1 influenza challenge. A lower dose of 1 mg/kg of 2-12C or a DNA plasmid-encoded version of 2-12C reduced pathology and viral load in the lungs but not viral shedding in nasal swabs. We propose that the pig influenza model will be useful for testing candidate mAbs and emerging delivery platforms prior to human trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.